In Vitro Diagnostic Market Report: 2025-2035
Technological advancements promote industry growth.
The field of in vitro diagnostics (IVD) continues to experience significant growth, driven by advancements in diagnostic technologies that improve accuracy, portability, and affordability. In May 2025, the U.S. Food and Drug Administration (FDA) approved the first blood test to assist in the diagnosis of Alzheimer's disease, marking a groundbreaking achievement. The "LUMIPULSE G pTau217/β-Amyloid 1-42 Plasma Ratio Test," developed by Fujirebio Diagnostics, offers a less invasive and more accessible alternative to traditional diagnostic methods such as PET scans and spinal taps by measuring specific biomarkers associated with Alzheimer's disease. This approval is expected to enhance early detection and management of Alzheimer's disease, particularly benefiting the elderly population. 【Contents】 ■ Market Overview ■ Impact of U.S. Trade Tariffs ■ Market Analysis (by Product, by Test, by Application, by End User) ■ Regional Market Analysis ■ Company Profiles
- 企業：データリソース
- 価格：500,000 yen-1 million yen
